HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
FRIDAY, May 6, 2022 (HealthDay News) -- An antiviral drug used to treat high-risk COVID-19 patients may also benefit patients with long COVID, researchers say. The research was posted on a preprint server online and has not been published in a peer-reviewed journal.
Paxlovid has U.S. Food and Drug Administration emergency use authorization to treat COVID-19 patients who are older than 65 years or have underlying health conditions such as obesity, diabetes, or cancer. The pill includes the antivirals nirmatrelvir and ritonavir. Treatment with Paxlovid must start within five days of the onset of symptoms and continue for five days, according to conditions of the authorization.
Now, a series of case reports from researchers at the University of California, San Francisco (UCSF) shows some success with Paxlovid in treating patients with long COVID. One-third of people infected with COVID-19 are thought to develop symptoms such as fatigue, headaches, and brain fog associated with long COVID. It is thought that long COVID may be caused by the immune system's ongoing reaction to the virus that remains in the body after the initial infection phase.
The case reports included three patients in their 40s who had symptoms consistent with long COVID. Two started taking Paxlovid weeks after the start of long COVID symptoms, contrary to the emergency authorization conditions. One was prescribed the antiviral after re-exposure to the virus more than seven weeks after symptom onset, and his health improved to near-normal, according to the researchers. The other patient took Paxlovid about three weeks after symptom onset. She felt less fatigued the day after completing therapy but still had shortness of breath and muscle pain.
The third patient started taking Paxlovid within 24 hours of the start of COVID-19 symptoms, in line with the emergency use conditions. His symptoms improved, but returned four days after he completed Paxlovid therapy, with fever, runny nose, cough, and chest pain. He also had elevated temperature and heart and respiratory rates. About two weeks later, he developed brain fog, chest soreness, fatigue, and discomfort after exertion -- symptoms consistent with long COVID.
"The key aspect of this case is that longer courses of Paxlovid may be needed, and giving it too early might not be optimal," study coauthor Michael Peluso, M.D., of UCSF and the Zuckerberg San Francisco General Hospital, said in a news release, noting that there are no safety data yet to support extended use of the drug. "Only by doing rigorous studies will we get answers," he added. "There is a critical need for this, given the large number of people who have had COVID, a significant subset of whom have long COVID."
- Rare Cases of COVID Relapse Seen With Pfizer Pill - Consumer Health News | HealthDay ›
- COVID Can 'Rebound' After Treatment With Paxlovid, CDC Says - Consumer Health News | HealthDay ›
- La COVID puede 'resurgir' tras el tratamiento con Paxlovid, señalan los CDC - Consumer Health News | HealthDay ›
- U.S. Making It Easier to Access COVID Treatment Paxlovid - Consumer Health News | HealthDay ›
- EE. UU. facilitará el acceso a Paxlovid, un tratamiento contra la COVID - Consumer Health News | HealthDay ›
- People With Diabetes 4 Times More Prone to Long COVID - Consumer Health News | HealthDay ›
- Las personas con diabetes tienen cuatro veces más probabilidades de COVID prolongada - Consumer Health News | HealthDay ›
- COVID Symptoms Rarely Rebound After Paxlovid Treatment: Study ›
- Los síntomas de COVID raras veces repuntan tras el tratamiento con Paxlovid, según un estudio - Consumer Health News | HealthDay ›
- Long COVID Could Be Half as Likely With Omicron vs. Delta - Consumer Health News | HealthDay ›
- Quizá haya la mitad de probabilidades de COVID prolongada con la ómicron que con la delta - Consumer Health News | HealthDay ›
- Paxlovid Cuts Odds for Hospitalization After Omicron Infection by 45% - Consumer Health News | HealthDay ›
- Fauci Has 'Rebound' COVID After Paxlovid, But Says Drug Kept Him Out of the Hospital - Consumer Health News | HealthDay ›
- NYC First to Offer Paxlovid at COVID Testing Sites - Consumer Health News | HealthDay ›
- Fauci tiene un 'rebote' de la COVID tras tomar Paxlovid, pero afirma que el fármaco lo salvó del hospital - Consumer Health News | HealthDay ›
- La ciudad de Nueva York será la primera en ofrecer Paxlovid en los centros de pruebas - Consumer Health News | HealthDay ›
- FDA Allows Pharmacists to Prescribe COVID Drug Paxlovid - Consumer Health News | HealthDay ›
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 25, 2022